Rxivist logo

Systems genetics identifies modifiers of Alzheimer's disease risk and resilience

By Sarah M. Neuner, Timothy J Hohman, Ryan Richholt, David A. Bennett, Julie A Schneider, Philip L De Jager, Matthew J. Huentelman, Kristen M. S. O’Connell, Catherine C. Kaczorowski

Posted 27 Nov 2017
bioRxiv DOI: 10.1101/225714

Identifying genes that modify symptoms of Alzheimer's disease (AD) will provide novel therapeutic strategies to prevent, cure or delay AD. To discover genetic modifiers of AD, we combined a mouse model of AD with a genetically diverse reference panel to generate F1 mice harboring identical high-risk human AD mutations but which differ across the remainder of their genome. We first show that genetic variation profoundly modifies the impact of causal human AD mutations and validate this panel as an AD model by demonstrating a high degree of phenotypic, transcriptomic, and genetic overlap with human AD. Genetic mapping was used to identify candidate modifiers of cognitive deficits and amyloid pathology, and viral-mediated knockdown was used to functionally validate Trpc3 as a modifier of AD. Overall, work here introduces a humanized mouse population as an innovative and reproducible resource for the study of AD and identifies Trpc3 as a novel therapeutic target.

Download data

  • Downloaded 1,085 times
  • Download rankings, all-time:
    • Site-wide: 9,936 out of 88,562
    • In genetics: 678 out of 4,591
  • Year to date:
    • Site-wide: 33,761 out of 88,562
  • Since beginning of last month:
    • Site-wide: 34,267 out of 88,562

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)